Cancer Vaccines Market Taking New Steps to Meet the Challenges With Major Key Companies
Cancer is the second
leading cause of morbidity and mortality worldwide. Major cause of
cancer is gene mutation and rarely due to inherited genes. On the
basis of the type of cell it initiates to form cancerous with, it is
divided into carcinoma, lymphomas, leukaemias, brain tumors, and
sarcomas. According to World Health Organization (WHO), 2017, nearly
1 in 6 deaths is due to cancer globally and around 70% of deaths from
cancer occur in low- and middle-income countries. Moreover, it is
projected that for next two decades, 70% of new cases are expected to
be diagnosed globally. Advent of cancer vaccines can significantly
reduce this numbers and lead a cancer-free life for the global
population.
Key players in the
global cancer vaccines market include, Astrazeneca Plc. (Medimmune,
LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur,
Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL
Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.
Download the PDF
brochure:
Global Cancer
Vaccines Market Taxonomy:
By Product Type:
Preventive cancer vaccines, Therapeutic cancer vaccines
By Technology:
Subunit Vaccines, Live Attenuated Vaccines, Conjugate Vaccines,
Inactivated Vaccines, Recombinant Vector Vaccines, Viral Vector And
DNA Cancer Vaccine,
By Application:
Cervical cancer, Prostate cancer And Others
Development of new
vaccines for treatment of different cancers is expected to fuel
growth of the cancer vaccines market over the forecast period
Manufacturers in the
cancer vaccines market are focusing on developing new vaccines in
order to treat various cancers. Through this, they are expected to
gain a competitive edge in the market and increase their market
share. For instance, Gilead Science Inc., in 2017, acquired Kite
Pharma Inc., which is involved in development of different type of
immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated
with Pharmaceutical Product Development, LLC (PPD), in order to
conduct its first-in-human clinical trial for its cancer vaccine for
metastatic colorectal cancer.
Increasing
prevalence and incidence of different cancers is expected to favor
growth of the cancer vaccines market
According to WHO, in
2015, about 8.8 million people died from cancer. Moreover, tobacco
related cancers was responsible for 22% deaths, lung cancer accounted
for 1.69 million deaths, liver cancer led to 788,000 deaths.
Colorectal, stomach, and breast cancer are estimated to cause
774,000, 754,000, and 571,000 deaths, worldwide. Increasing
prevalence is a major driving factor to fuel growth of the cancer
vaccines market.
According to a
research from University of Pittsburgh School of Medicine, in 2017, a
high dose flu vaccine can be used to treat people aged between 54–64
years with chronic condition such as heart disease, lung disease,
diabetes, and cancer. The study is recommended for clinical trials in
geriatric population.
Also, in 2017, Swiss
Biotech, developed VXM01 — an attenuated bacterial vaccine modified
to express vascular endothelial growth factor receptor-2 (VEGFR2),
stimulates cytotoxic (killer) T cells, which will destroy cells in
the vasculature feeding tumor and allow greater infiltration of
immune cells. This vaccine is expected to be used for treatment in
colorectal cancer and glioblastoma. Click To Read More On
Cancer
Vaccines Market
Comments
Post a Comment